Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Comment by prophetoffactzon Jul 04, 2024 11:33am
76 Views
Post# 36118165

RE:Perplexity Ai on the potential of a wound healing franchise

RE:Perplexity Ai on the potential of a wound healing franchise
  1. Targeting inflammation and fibrosis:
    The unique mechanism of action discovered for PGX yeast beta glucan in addressing inflammation and fibrosis through macrophage modulation could be a key differentiator for Ceapro's wound healing franchise. This approach could lead to the development of products that not only promote healing but also manage excessive scarring and fibrosis.
Macrophages play a crucial role in wound healing:
  1. Inflammation phase: Macrophages are among the first cells to arrive at the wound site, where they phagocytose debris and release pro-inflammatory cytokines to initiate the healing process.
  2. Proliferation phase: Macrophages transition to a pro-healing phenotype, promoting angiogenesis, fibroblast proliferation, and extracellular matrix deposition.
  3. Remodeling phase: Macrophages continue to regulate the healing process, promoting tissue remodeling and helping to restore normal tissue architecture.
  4. Scar formation: Macrophages influence the degree of scarring by regulating fibroblast activity and collagen deposition.
By targeting macrophage function with their PGX yeast beta glucan, Ceapro could potentially develop products that modulate the wound healing process at multiple stages, promoting faster healing, reducing inflammation, and minimizing scarring.To create a comprehensive wound healing franchise, Ceapro could:
  1. Conduct further clinical trials to validate the efficacy of their compounds in various wound types.
  2. Develop a range of products for different wound healing applications.
  3. Seek regulatory approvals for medical-grade wound healing products.
  4. Partner with healthcare providers and wound care specialists to establish their products in clinical settings.
  5. Educate healthcare professionals and consumers about the benefits of their natural, macrophage-modulating approach to wound healing.
By leveraging their existing research and technologies, Ceapro has the potential to create a unique and effective wound healing franchise that addresses multiple aspects of the wound healing process.
<< Previous
Bullboard Posts
Next >>